Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations

Background There is a resurgence of interest in home hemodialysis (HD), especially frequent or extended forms involving unconventionally frequent (>3 times/wk) and/or long (>6 hours) treatments. This resurgence is driven by cost containment and experience suggesting lower mortality risk compar...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of kidney diseases Vol. 58; no. 5; pp. 782 - 793
Main Authors Marshall, Mark R., MBChB, MPH(Hons), FRACP, Hawley, Carmel M., MB,BS(Hons), MMedSci, FRACP, Kerr, Peter G., MB,BS, PhD, FRACP, Polkinghorne, Kevan R., BHB, MBChB, MClinEpi, PhD, FRACP, Marshall, Roger J., PhD, Agar, John W.M., MB,BS, FRCP(Lond), FRACP, McDonald, Stephen P., MB,BS(Hons), PhD, FRACP
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.11.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background There is a resurgence of interest in home hemodialysis (HD), especially frequent or extended forms involving unconventionally frequent (>3 times/wk) and/or long (>6 hours) treatments. This resurgence is driven by cost containment and experience suggesting lower mortality risk compared with facility HD and peritoneal dialysis (PD). Study Design We performed an observational cohort study using the Australia and New Zealand Dialysis and Transplant Registry, using marginal structural modeling to adjust for time-varying medical comorbidity as both a source of selection bias and an intermediary variable on the causal pathway to death. Setting & Participants All adult patients starting renal replacement therapy in Australia and New Zealand since March 31, 1996, followed up to December 31, 2007. Predictor The main predictor was dialysis modality (conventional facility HD, conventional home HD, frequent/extended facility HD, frequent/extended home HD, and PD). We adjusted for the confounding effects of patient demographics and comorbid conditions. Outcome Patient mortality. Results We analyzed 26,016 patients with 856,007 patient-months of follow-up. Relative to conventional facility HD, adjusted mortality HRs were 0.51 (95% CI, 0.44-0.59) for conventional home HD, 1.16 (95% CI, 0.94-1.44) for frequent/extended facility HD, 0.53 (95% CI, 0.41-0.68) for frequent/extended home HD, and 1.10 (95% CI, 1.06-1.16) for PD. The apparent benefit of home HD on mortality risk was less for patients who were nonwhite, non-Asian, and older. Limitations Potential for residual confounding from the limited collection of comorbid conditions (no collection of cognitive or motor impairment, depression, left ventricular volume or structure, or blood pressure/fluid volume status) and lack of socioeconomic, medication, and biochemical data in analyses. Conclusions Our study supports a survival advantage of home HD without a difference between conventional and frequent/extended modalities. Suitably designed clinical trials of frequent/extended HD are needed to determine the presence and extent of mortality benefit with this modality.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0272-6386
1523-6838
DOI:10.1053/j.ajkd.2011.04.027